We report here a distinct mechanism of interaction between topoisomerase I and RNA polymerase in Mycobacterium tuberculosis and Mycobacterium smegmatis that has evolved independently from the previously characterized interaction between bacterial topoisomerase I and RNA polymerase. Bacterial DNA topoisomerase I is responsible for preventing the hyper-negative supercoiling of genomic DNA. The association of topoisomerase I with RNA polymerase during transcription elongation could efficiently relieve transcription-driven negative supercoiling. Our results demonstrate a direct physical interaction between the C-terminal domains of topoisomerase I (TopoI-CTD) and the β′ subunit of RNA polymerase of M. smegmatis in the absence of DNA.
Introduction
Topoisomerases are essential enzymes that are responsible for controlling DNA topology and facilitating vital cellular processes that include replication, transcription, recombination, and DNA repair [1] [2] [3] [4] [5] . The active site for DNA cleavage and rejoining by type IA topoisomerases is evolutionarily conserved at the N-terminal domains of bacterial topoisomerase I and topoisomerase III 6, 7 . Bacterial topoisomerase I is responsible for relieving the transcription-driven negative supercoiling, generated behind the RNA polymerase complex during transcription elongation [8] [9] [10] . The absence of topoisomerase I activity in Escherichia coli has been shown to result in increased R-loop formation via the stable association of the nascent transcript with the unwound DNA 11, 12 . This could potentially block transcription elongation 13, 14 . A direct association between RNA polymerase and topoisomerase I would facilitate gene expression at highly transcribed loci, including genes induced for survival in stress response.
It was previously reported that the E. coli RNA polymerase β′ subunit interacts directly with the zinc ribbon and zinc ribbon-like C-terminal domains (CTD) of topoisomerase I 15, 16 . In E. coli and most bacterial species, the CTD of topoisomerase I have multiple zinc ribbon domains, each with a Zn(II) ion coordinated by four cysteines [17] [18] [19] . In contrast, the topoisomerase I proteins in Actinobacteria, including mycobacteria, evolved with TopoI-CTD that do not have zinc ribbon or zinc ribbon-like domains 20, 21 . Structural determination by X-ray crystallography showed that the Mycobacterium tuberculosis topoisomerase I CTD are formed by repeats of a novel protein fold of a four-stranded antiparallel β-sheet, stabilized by a crossing-over α-helix 22 . We speculated that the CTD of mycobacterial topoisomerase I could be involved in protein-protein interactions, among its other functions. The protein-protein interactions of topoisomerase I from M. smegmatis were studied by co-immunoprecipitation (Co-IP) and pull-down assays coupled to tandem mass spectrometry [23] [24] [25] [26] . The assays identified an interaction between DNA-dependent RNA polymerase (RNAP), and topoisomerase I in M. smegmatis. This TopoI-RNAP interaction
Results

Identification of RNAP as protein-protein interaction partner of MsmTopoI
The protein-protein interaction network of the target protein (MsmTopoI) was first analyzed by Co-IP ( Figure 1 ) coupled to mass spectrometry. Antibodies raised against MtbTopoI also recognized MsmTopoI ( Figure S1 ). Following SDS-PAGE of the proteins immunoprecipitated by these antibodies from the soluble lysate of M. smegmatis, coomassie-stained proteins labeled as a-d in lane 5 of Figure 1B were selected. The control purified pre-immune antibodies did not precipitate the proteins corresponding to the bands ad, as evident in lane 4 ( Figure 1B ). The ability of the antibodies raised against MtbTopoI to immunoprecipitate MsmTopoI from the cell lysate was confirmed by western blot analysis of the Co-IP eluates ( Figure 1C ). LC MS/MS analysis identified M. smegmatis RNAP β and β′ subunits in protein band a (Supplementary material, S5 ).
Protein networking of MsmTopoI was further investigated by pull-down assays as described in Figure 2A with His-tagged MsmTopoI and MsmTopoI-CTD. Coomassie-stained proteins (e, f in lanes 7 and 8, Figure 2B ) of M. smegmatis pulled down by either His-tagged MsmTopoI or MsmTopoI-CTD, but not control His-Mocr (lane 6, Figure 2B ), were analyzed by LC MS/MS. M. smegmatis RNAP β and β′ subunits were again identified in protein band e.
Protein-protein interaction between RNAP and topoisomerase I in M. smegmatis was further verified by reverse pull-down followed by immunoblotting ( Figure 2C ). In this assay, recombinant RNAP β′ subunit (N-terminal 6xHis) was used as a bait to capture topoisomerase I from the M. smegmatis soluble cell lysate. The assay confirmed a concentration-dependent binding between the two proteins (lanes 3-5 in Figure 2C ). The combined results from Co-IP and pull-down experiments confirmed the networking of topoisomerase I and RNAP with a distinct mode of protein-protein interaction that does not involve the zinc ribbon domains found in other bacterial topoisomerase I.
RNAP-Topoisomerase I interactions are conserved in M. tuberculosis H37Rv
M. smegmatis is a useful model system for the understanding of processes in pathogenic M. tuberculosis 27, 28 . The protein-protein interaction between topoisomerase I and RNAP could be conserved among these mycobacteria. The RNAP-topoisomerase I interaction in M. tuberculosis H37Rv was studied by pull-down ( Figure 3A ) and Co-IP assays ( Figure 3B ).
Results from both approaches (lane 2 in Figure 3A ; lanes 2, 3 in Figure 3B ) confirmed the conservation of the RNAP-topoisomerase I interaction in M. tuberculosis.
Direct physical interaction between Topoisomerase I and RNAP β′ subunit
The results from the Co-IP and pull-down experiments indicate the presence of mycobacterial topoisomerase I and RNAP in the same complex. However, a direct physical interaction between these two partners in the absence of DNA or other mycobacterial proteins was not established. The direct protein-protein interactions were analyzed with purified recombinant proteins.
Physical interaction between the M. smegmatis RNAP β′ subunit and topoisomerase I was demonstrated by both co-immunoprecipitation ( Figure 4A ) and pull-down experiments ( Figure 4B ). This protein-protein interaction is specific. No interaction with MsmTopoI could be observed for M. smegmatis RNAP β subunit ( Figure 4A ). E. coli topoisomerase I, with CTD that share no homology with MsmTopoI, also did not interact with the M. smegmatis RNAP β′ subunit ( Figure S2 ).
Mapping of MsmTopoI sequence required for interaction with RNAP
Pull-down ( Figure 5A ) and Co-IP ( Figure 5B ) assays were first conducted to verify that only the CTD (D5-D8, plus tail at C-terminal end), but not the NTD (D1-D4) of MsmTopoI are involved in the protein-protein interaction with RNAP. Pull-down assays with purified recombinant His-tagged proteins retaining different regions of the CTD of MsmTopoI as bait were then used to further identify the sequence in MsmTopoI-CTD required for pull-down of RNAP (prey) from the soluble cell extract. The pull-down of RNAP (prey) by proteinprotein interaction could be observed only when the full-length MsmTopoI, or MsmTopoI-CTD was used as the bait ( Figure 5C ; lanes 2, 8). Equal molar amounts of the bait protein (subdomains of topoisomerase I) were used in these assays. MsmTopoI-909t (D1-D8) of topoisomerase I is only missing the tail at the C-terminal end (last 27 amino acids), but it still lacks affinity for RNAP. This data indicated that the protein-protein interaction with RNAP is mediated via the C-terminal tail sequence (amino acids 910-936) of MsmTopoI ( Figure 5D ).
Increased sensitivity to antibiotics and oxidative stress from overexpression of MsmTopoI-CTD
Overexpression of the MsmTopoI-CTD is expected to inhibit the interaction between native MsmTopoI and RNAP due to its competition for binding. Following tetracycline-induced overexpression of recombinant MsmTopoI-CTD in M. smegmatis mc 2 155 ( Figure 6A ), less full-length MsmTopoI was pulled down by the His-tagged RNAP β′ subunit ( Figure 6B ). The MsmTopoI-CTD overexpression did not affect the growth rate in 7H9 media in the absence of any stress challenge, however, growth rate was reduced by the MsmTopoI-CTD overexpression in the presence of sublethal concentration of moxifloxacin ( Figure S3 ). Increased sensitivity to stress challenges from antibiotics (moxifloxacin, streptomycin, isoniazid) and hydrogen peroxide resulted from the MsmTopoI-CTD overexpression, as seen from the comparison of the diameters of the zones of inhibition between the control strain and MsmTopoI-CTD overexpressing strain ( Figure 7A ). No significant effect from MsmTopoI-CTD overexpression was observed for sensitivity to rifampicin (data not shown). This is likely because stress gene transcription is already inhibited by rifampicin. Following treatment with either moxifloxacin (0.5 μM, 1 μM) or hydrogen peroxide (10 mM, 20 mM), loss of viability was significantly greater for the MsmTopoI-CTD overexpressing strain when compared to the control strain ( Figure 7B ). These results showed that inhibition of the MsmTopoI-CTD protein-protein interactions can be correlated to enhanced sensitivity to antibiotics and oxidative stress.
Discussion
Most bacterial species have at least two type IA topoisomerases encoded in their genome 29, 30 to carry out specific associated functions in replication, transcription, and recombination that require the passage of DNA through a break in a single strand of DNA 3 . TopoI is the only type IA topoisomerase encoded in the genomes of mycobacteria, and has been shown to be essential for the viability of both M. tuberculosis 31, 32 and M. smegmatis 33 . The identification of the protein-protein interaction partners of mycobacterial TopoI is likely to provide insights into the in vivo functions and regulation of this potential antibacterial target. It has been reported that the relaxation activity of MtbTopoI and MsmTopoI can be inhibited by interaction with a MazF homolog 34 , as well as Dribokinase 35 . The catalytic activity of MtbTopoI can also be modulated by interaction with the nucleoid associated protein HU 36 . These previously identified protein-protein interactions may be relevant for the regulation of mycobacterial TopoI activity. However, experimental data on protein-protein interactions of mycobacterial TopoI that may inform on the physiological setting of its function 37 is currently not available. In this study, we tried to identify such potential partners present in the total soluble proteins of M. smegmatis using the approaches of Co-IP and pull-down assays coupled to mass spectrometry. RNAP was identified as a protein-protein interaction partner for MsmTopoI by both approaches. A recent ChIP-Seq study showed that M. tuberculosis TopoI and gyrase are recruited to genomic loci with high transcriptional activity, and MtbTopoI was localized behind RNAP to be in position for relaxing the negative supercoils generated during transcription 38 . Our studies here demonstrated that M. tuberculosis RNAP can recruit TopoI via protein-protein interaction to facilitate the co-localization during transcription elongation.
While protein-protein interaction with the RNAP β′ subunit has been previously reported for the CTD of E. coli TopoI 15 , it should be noted that the CTD of mycobacterial TopoI share no sequence and structural similarity with the CTD of bacteria outside the Actinobacteria phylum 39, 21 . The CTD of E. coli TopoI are formed by zinc ribbon motifs stabilized by Zn(II) coordinated with four cysteines in each motif (D5-D7), or zinc ribbon-like motifs of similar structures (D8-D9) 17, 18 . Interaction sites for RNAP have been mapped to E. coli TopoI CTD regions of D5-D7 as well as D8-D9 15 . Analysis of the MsmTopoI protein sequence 40 and determination of the D1-D5 structure of MtbTopoI 22 have shown that the CTD of mycobacteria are formed by repeats of a distinctively different structural motif containing a β-sheet and α-helix, with no Zn(II) present. The results reported here demonstrate that while the different bacterial species have evolved to have distinct sequences and structures of the CTD in TopoI, potentially through acquiring different duplicated gene segments during evolution 41 , the protein-protein interaction with the β′ subunit of RNAP has simultaneously co-evolved through divergent mechanisms in different bacterial phylum.
Molecular simulations predicted that salt bridges and hydrogen bonds formed by basic residues positioned over a large molecular surface formed by the zinc ribbon motifs of E. coli TopoI are responsible for interactions with acidic residues in RNAP 16 . In contrast, a distinct mode of protein-protein interaction utilizing a short stretch of C-terminal tail is employed instead for the TopoI-RNAP interaction in bacteria that do not have Zn(II) binding TopoI-CTD. As shown in Figure S4 , the amino acid sequence of this C-terminal tail is highly conserved in mycobacterial TopoI and is rich in basic residues. The basic region represented by the C-terminal tail of MsmTopoI and MtbTopoI has been proposed to participate in the binding of DNA to promote strand passage during catalysis 20, 42 . Direct interaction of the C-terminal tail with RNAP would facilitate the rewinding of singlestranded DNA following its exit from the RNAP elongation complex to prevent stabilization of R-loop structures and inhibition of transcription elongation. The TopoI-RNAP interaction may be particularly important for efficient transcriptional response to stress conditions to achieve maximal survival following antibiotics or oxidative challenge 14, 43 . Competition for RNAP interaction by overexpressed recombinant MsmTopoI-CTD may have contributed to the increase in sensitivity to antibiotics and oxidative stress challenge observed here. Inhibition of the SOS response induction following moxifloaxcin treatment would result in the decreased survival for the MsmTopoI-CTD overexpressing strain. Nevertheless, we cannot rule out that other protein-protein interactions inhibited by overexpressed MsmTopoI-CTD may also contribute to the increased sensitivity. Other potential proteinprotein interaction partners identified in our Co-IP and pull down experiments are currently being investigated in further studies. Mycobacterial topoisomerase I may have functional roles associated with topoisomerase III in bacteria that have this additional type IA topoisomerase. The actinobacterium Streptomyces coelicolor also does not have topoisomerase III, and it has been hypothesized that S. coelicolor topoisomerase I is recruited to ParB complexes because the topoisomerase activity is needed to resolve segregating chromosomes 44 .
Based on the essentiality of topoisomerase I for the viability of M. tuberculosis, MtbTopoI is a validated target for discovery of novel TB drugs 32, 45 . The SOS response has been shown to be involved in the induction of mycobacterial resistance to fluoroquinolones 46 . Due to its involvement in transcriptional response to stress challenges, mycobacterial topoisomerase I inhibitors could be especially useful for use in combination with other antibiotics to increase the efficacy, and decrease the induction of drug resistance.
Materials and methods
Bacterial strains, plasmids, and cloning M. smegmatis mc 2 155 was obtained from ATCC and cultured in 7H9 broth. M. tuberculosis
H37Rv genomic DNA and whole cell lysates were obtained from BEI Resources. A plasmid pMsmTopoI-CTD for overexpression of topoisomerase I-CTD in M. smegmatis was constructed by first placing M. smegmatis topA coding sequence (amplified with primers shown in Table S1 ) under the control of the tetracycline inducible TetRO promoter in pKW08 vector 47 via Gibson Assembly cloning 48 . Plasmid pMsmTopoI-CTD was then constructed for overexpression of the C-terminal domains D5-D8 plus tail (residues 627-936) by deleting the N-terminal domains D1-D4 (residues 1-626) via site-directed mutagenesis. Overexpression of the various domains of M. smegmatis topoisomerase I (MsmTopoI) in E. coli BL21 STAR DE3 (Invitrogen) was achieved with pET His6 Mocr TEV LIC cloning vector (2O-T, Addgene Plasmid# 29710). Cloning of recombinant M. tuberculosis topoisomerase I (MtbTopoI) and its CTD in vector pLIC-HK 49 for expression in E. coli BL21-CodonPlus(DE3)-RP (Agilent) was described previously 50 . Coding sequences for M. smegmatis RNAP β (RpoB) and β′ (RpoC) subunits were inserted by Gibson cloning into the SspI site of pLIC-HK, and transformed into E. coli SoluBL21 (Genlantis) cells for protein expression and purification. The PCR primers used in the cloning and site-directed mutagenesis are listed in the Supplementary Information (Table S1 and Table S2 ).
Protein expression and purification
DNA topoisomerase I, sub-domains of topoisomerase I, RNAP β, and RNAP β′ subunits were purified as recombinant proteins for protein-protein interaction studies. Overexpression of these recombinant proteins in the E. coli hosts was induced with 1 mM IPTG. Following the overexpression and cell lysis, recombinant proteins were purified to near homogeneity by affinity chromatography using Ni-Sepharose 6 Fast flow beads (GE Healthcare Life Sciences), followed by size-exclusion chromatography.
Co-Immunoprecipitation (Co-IP)/Tandem Mass spectrometry
The complex of M. smegmatis topoisomerase I (MsmTopoI) and its potential protein partners was isolated from the M. smegmatis soluble cell lysate by Co-IP 23 . M. smegmatis mc 2 155 was grown to stationary phase in LB-Tween 80 (0.1%). The pelleted cells were resupsended in lysis/wash buffer (50 mM NaCl, 50 mM NaH 2 PO 4 , pH 8.0, 0.1% NP-40), and then subjected to 5 pulses of sonication (10 seconds/pulse at medium intensity). The lysate was spun at 16000×g for an hour, and the supernatant soluble lysate was used as prey in the Co-IP assays. The soluble lysate was pre-incubated (pre-cleared) with protein A/G plus agarose beads to remove proteins that bind non-specifically to the beads. The precleared lysate (total protein=500 μg) was first mixed with IgG (10 μg) purified from serum of a rabbit inoculated with MtbTopoI or control pre-immune serum. These rabbit polyclonal antibodies cross react with MsmTopoI ( Figure S1 ). The protein A/G plus agarose beads (Santa Cruz Biotechnology), previously equilibrated in wash buffer, was then added to the lysate-antibody reaction and left overnight at 4°C. On the following day, the reaction mixture was spun at 700×g, and the supernatant was discarded. The bead pellet with the bound proteins was washed three times in the wash buffer. The elution of the proteins bound to the beads was carried out by suspending the bead pellet in 4X SDS sample buffer (240 mM Tris-HCl, 8% SDS, 40% glycerol, 0.04% bromophenol blue), and heating at 95°C for 2 minutes. The eluted proteins (MsmtopoI, and its potential protein partners) were stained with coomassie blue following SDS-PAGE. The protein bands of interest were excised for characterization by tryptic digest and mass spectrometry (nano LC/MS/MS) at the Proteomics and Mass Spectrometry Facility of University of Massachusetts Medical School. The MS/MS results were searched using Mascot (Matrix Science, London, UK; version 2.5.0) against the UniProt_MSmegmatis_071714 database for trypsin digestion products.
Pull-down assay/Tandem Mass spectrometry
For the pull-down assay 24 , the target protein (MsmtopoI) with a fusion tag (N-terminal 6xHistidine) was mixed with M. smegmatis mc 2 155 soluble cell extract for 2 hours at 4°C, and then immobilized on a HisPur Cobalt agarose resin (Thermofisher). The resin with bound target proteins was washed three times in a pull-down wash buffer (10 mM HEPES, pH 7.5, 10 mM imidazole, 0.005% Tween-20) to remove the weakly retained proteins. The proteins that remained bound to the resin were eluted with pull-down elution buffer (10 mM HEPES, pH 7.5, 350 mM imidazole), separated by SDS-PAGE, and stained with coomassie blue. The protein bands of interest were excised for identification by tryptic digest and nano LC/MS/MS.
Reverse pull-down assay/Immunoblotting
A reverse pull-down assay was used to validate the protein interactions identified by pulldown assays. In this assay, a recombinant M. smegmatis RNAP β′ subunit (N-terminal 6xHistidine) was used as bait to pull down topoisomerase I from the soluble cell extract. The pull-down protocol was similar to that described in the previous section. Western blot analysis with rabbit polyclonal antibodies against MtbTopoI was used to detect the presence of topoisomerase I in the eluate.
Pull-down, Co-IP assays on M. tuberculosis (H37Rv) cell extract
The conservation of RNAP-topoisomerase I protein-protein interactions in M. tuberculosis was verified by pull-down and Co-IP assays. Whole cell extract of M. tuberculosis H37Rv was provided by BEI Resources. The extract was spun at 16000×g for 20 min at 4°C, and the soluble protein fraction was used for the assays. Recombinant MtbTopoI with N-terminal 6x-Histidine was used in the pull-down assay, while antibodies against topoisomerase I were used in the Co-IP assay as bait to determine if RNAP could be captured from the cell extract. Following SDS-PAGE, the proteins in the eluates from the assays were immunoblotted with a monoclonal antibody against RNAP β (Biolegend) which can recognize the RNAP β subunits 51 across multiple species, including M. tuberculosis and M. smegmatis.
Effect of TopoI-CTD overexpression on sensitivity to antibiotics or hydrogen peroxide
The M. smegmatis strain overexpressing the CTD of topoisomerase I from the plasmid pMsmTopA-CTD, or a control M. smegmatis strain transformed with the cloning vector, were cultured to stationary phase in 7H9 medium containing Hygromycin (100μg/ml) and tetracycline (25ng/ml). The cultures were adjusted to OD 600 =1.0 in 7H9 medium, and 200μl of the OD-adjusted culture was spread on LB plates. Antibiotic or H 2 O 2 was applied to paper discs placed at the center of the plates, followed by incubation at 37°C for 60 hrs. The diameter of the zone of inhibition was measured.
For comparison of viable colony counts following stress challenge, the M. smegmatis strains were grown in Luria broth-Tween 80 (0.1%) containing Hygromycin (100μg/ml) and tetracycline (25ng/ml). At the exponential phase, the cultures were treated with moxifloxacin (0.5 μM or 1 μM) for 12 hours at 37°C. The treated cultures and untreated cultures were serially diluted and spread on LB plates. The viable colonies were counted, and the relative viability ratio (treated versus untreated) was calculated. Similarly, viable colony counts following treatment with hydrogen peroxide (10 mM or 20 mM) was analyzed with the strains cultured in 7H9 medium containing Hygromycin (100 μg/ml) and tetracycline (25 ng/ml). (A) The tetracycline-induced cultures of the vector control strain (control), and the MsmTopoI CTD-overexpression strain (CTD-OE) were spread on LB plates, and a blank paper disc was placed on the plate. 20 μL of the antibiotic solution or hydrogen peroxide was added to the disc. The plates were incubated at 37°C for 60 hours, and the zone of inhibition was measured. Error bars represent the standard deviation (n=3). Student's t-test was used to calculate the p-values (* p<0.05; ** p<0.005, ***p<0.0005). (B) Following treatment with moxifloxacin or hydrogen peroxide for 12 hours, the untreated and treated cultures of the tetracycline-induced vector control strain (control), and MsmTopoI CTDoverexpression (CTD-OE) strain were serially diluted and spread on LB plates. The viable colony counts (CFU/ml) were determined to calculate the relative survival ratios as the colony counts of the treated cultures divided by the colony counts of the untreated cultures. 
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